Theseare antipsychotics drugs (except TB and MB) often used in schizophreniapatients, and there is epidemiological evidence that has linked lowercancer incidence in schizophrenia patients to long-term medication,highlighting the anticancer potential of antipsychotics. Notably, only TFP and CPZ have been previouslyrecognized for their ability to inhibit MT assembly,, yet all these derivatives have been either demonstrated or hypothesizedto possess anticancer properties, despite their primary classificationas CNS therapeutics targeting dopamine receptors. Here, CPZ is linked to schizophrenia.